BOSTON — Ear­ly last year, start­up iECURE’s ex­per­i­men­tal gene ther­a­py seem­ing­ly cured a ba­by of a life-threat­en­ing ge­net­ic dis­ease.

But new re­sults test­ing the same...

Take­da will cut rough­ly 9% of its work­force over the next fis­cal year as the next CEO puts her stamp on a years­long re­struc­tur­ing.

About...

French vac­cine mak­er Val­ne­va is lay­ing off 10% to 15% of its work­force and re­duc­ing rev­enue pro­jec­tions due to "an emerg­ing ad­verse trend in trav­el...

Mar­ty Makary nev­er stood a chance.

Over the last few days, the now-for­mer FDA com­mis­sion­er had been left to twist in the wind, af­ter head­lines...

CHICA­GO — From a 22nd-floor of­fice over­look­ing the Chica­go River­walk, in the heart of the Mid­west hub’s white-col­lar down­town dis­trict, Lake­front Bio­ther­a­peu­tics’ ex­ec­u­tives hope to...